Size Li, Xu Zhu, Guoying Cao, Jufang Shen, Xu Zhu, Jicheng Yu, Xiaojie Wu, Jufang Wu, Haijing Yang, Nanyang Li, Yingying Hu, Jingjing Wang, Haihui Huang, Jing Zhang
EVER206 (also known as SPR206) is a novel polymyxin analog that has shown in vitro potency and in vivo efficacy against multidrug-resistant (MDR) Gram-negative pathogens. This randomized, double-blinded, placebo-controlled, Phase I study evaluated the safety, tolerability, and pharmacokinetics of EVER206 in healthy Chinese subjects. After single administration of 50-300 mg EVER206, the Cmax ranged from 3.94 to 25.82 mg/L, and the AUC0-inf ranged from 12.42 to 101.67 h·mg/L. The plasma exposure displayed a linear relationship with the dose administered...
April 22, 2024: Antimicrobial Agents and Chemotherapy